Celltrion Pharm Inc - Asset Resilience Ratio
Celltrion Pharm Inc (068760) has an Asset Resilience Ratio of 12.49% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Celltrion Pharm Inc for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2024)
This chart shows how Celltrion Pharm Inc's Asset Resilience Ratio has changed over time. See Celltrion Pharm Inc (068760) shareholders funds for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Celltrion Pharm Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Celltrion Pharm Inc (068760) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩93.17 Billion | 12.49% |
| Total Liquid Assets | ₩93.17 Billion | 12.49% |
Asset Resilience Insights
- Moderate Liquidity: Celltrion Pharm Inc has 12.49% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Celltrion Pharm Inc Industry Peers by Asset Resilience Ratio
Compare Celltrion Pharm Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC |
Drug Manufacturers - Specialty & Generic | 43.05% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867 |
Drug Manufacturers - Specialty & Generic | 1.96% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Guobang Pharma Ltd
SHG:605507 |
Drug Manufacturers - Specialty & Generic | 8.47% |
Annual Asset Resilience Ratio for Celltrion Pharm Inc (2011–2024)
The table below shows the annual Asset Resilience Ratio data for Celltrion Pharm Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 9.48% | ₩63.48 Billion ≈ $43.02 Million |
₩669.46 Billion ≈ $453.69 Million |
+4.46pp |
| 2023-12-31 | 5.02% | ₩32.21 Billion ≈ $21.83 Million |
₩641.64 Billion ≈ $434.83 Million |
-2.33pp |
| 2022-12-31 | 7.35% | ₩44.09 Billion ≈ $29.88 Million |
₩599.72 Billion ≈ $406.42 Million |
-6.47pp |
| 2021-12-31 | 13.82% | ₩88.16 Billion ≈ $59.75 Million |
₩637.88 Billion ≈ $432.29 Million |
+8.39pp |
| 2020-12-31 | 5.43% | ₩29.75 Billion ≈ $20.16 Million |
₩548.07 Billion ≈ $371.42 Million |
+2.60pp |
| 2019-12-31 | 2.83% | ₩13.33 Billion ≈ $9.03 Million |
₩470.98 Billion ≈ $319.18 Million |
+0.82pp |
| 2018-12-31 | 2.02% | ₩9.12 Billion ≈ $6.18 Million |
₩452.44 Billion ≈ $306.61 Million |
+0.75pp |
| 2017-12-31 | 1.27% | ₩5.95 Billion ≈ $4.03 Million |
₩470.27 Billion ≈ $318.69 Million |
-0.79pp |
| 2016-12-31 | 2.06% | ₩10.51 Billion ≈ $7.12 Million |
₩510.02 Billion ≈ $345.63 Million |
+1.91pp |
| 2015-12-31 | 0.15% | ₩715.00 Million ≈ $484.55K |
₩466.77 Billion ≈ $316.32 Million |
-0.79pp |
| 2014-12-31 | 0.94% | ₩3.86 Billion ≈ $2.62 Million |
₩411.16 Billion ≈ $278.64 Million |
-0.66pp |
| 2013-12-31 | 1.60% | ₩5.78 Billion ≈ $3.92 Million |
₩361.35 Billion ≈ $244.88 Million |
-2.12pp |
| 2012-12-31 | 3.72% | ₩12.31 Billion ≈ $8.34 Million |
₩331.04 Billion ≈ $224.34 Million |
-2.99pp |
| 2011-12-31 | 6.70% | ₩14.49 Billion ≈ $9.82 Million |
₩216.08 Billion ≈ $146.43 Million |
-- |
About Celltrion Pharm Inc
Celltrion Pharm, Inc., a pharmaceutical company, develops and sells biosimilars and over-the-counter drugs in South Korea. The company offers hepatotonic, anti-inflammatory, antihistamine, respiratory apparatus, circulary system, digestive and stomachic, hormone/metabolic disease, antibiotic/antimycotic, nutrientia and tonic, immunology, oncology, and other drugs. It serves university hospitals a… Read more